Alexion aims to advance NMOSD treatment landscape with exceptional Ultomiris efficacy data at ECTRIMS 2022
Results from CHAMPION-NMOSD trial demonstrated zero relapses with a median treatment duration of 73 weeks.
Additional presentations will underscore debilitating emotional and physical toll of NMOSD on patients and caregivers, and highlight urgency to reduce disease burden.
Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, 26 to 28 October 2022.
Data presented at the meeting will feature new insights from Alexion’s complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses, including findings on the first and only long-acting C5 complement inhibitor, Ultomiris (ravulizumab).
Marc Dunoyer, Chief Executive Officer, Alexion, said: “NMOSD relapses are unpredictable and often cause permanent disability, including blindness, paralysis and even premature death. Our data build on the established role of complement inhibition in managing NMOSD and reinforce our commitment to patient-centred innovation. Results from the CHAMPION-NMOSD trial highlight the potential for Ultomiris to substantially reduce the risk of relapse and ease treatment burden for the community.”
Redefining NMOSD disease management
An oral presentation will showcase results of the CHAMPION-NMOSD trial, which evaluated the safety and efficacy of Ultomiris in adults with AQP4 Ab+ NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.
The data will show there were zero adjudicated on-trial relapses observed in patients with AQP4 Ab+ NMOSD with a median treatment duration of 73 weeks, representing a relapse risk reduction of 98.6% (p<0.0001) compared to the external placebo arm. The safety and tolerability of Ultomiris in the CHAMPION-NMOSD trial were consistent with previous clinical studies and other approved indications.
Improving understanding of the NMOSD patient experience
Two poster presentations detail findings from qualitative interviews with NMOSD patients. This work helps to inform the scientific community about the immediate and lasting impact of relapses, including ability to work and participate in daily activities, mobility and pain as well as reliance on caregiver support.
Alexion presentations during ECTRIMS 2022
| Lead author | Abstract title | Presentation details |
| Pittock, SJ | Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial | Oral Presentation O05127 October 202210:05 (CEST) |
| Pittock, SJ | Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder | Poster Presentation P01026 October 202216:30 (CEST)ePoster Tour 528 October 202214:00 (CEST) |
| Allen, K | Sensitivity analysis using propensity score methods for primary efficacy outcome in the CHAMPION-NMOSD trial | Poster Presentation P01226 October 202216:30 (CEST) |
| Palace, J | Mortality estimates in patients with anti-aquaporin-4 autoantibody positive neuromyelitis optica spectrum disorder | Poster Presentation P01826 October 202216:30 (CEST) |
| Kielhorn, A | Long-term burden of relapse in patients with AQP4+ NMOSD: simulation study based on network meta-analysis | Poster Presentation P01926 October 202216:30 (CEST) |
| Osborne, B | Activity impairment and support needs in patients with neuromyelitis optica spectrum disorder | Poster Presentation P41827 October 202217:00 (CEST) |
| Bernitsas, E | Understanding the symptoms of patients with neuromyelitis optica spectrum disorder and their impact on patient’s lives: a qualitative interview study | ePoster Presentation EP090126 October 2022 8:00 (CEST) |
Notes
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.